PSEN1 and Alzheimer disease: Consistent with our observation, (Dansokho et al., 2016) showed that using the 4–6-week-old AD mouse model (APP/PS1), the amplification of Tregs by peripheral chronic low-dose IL-2 administration restored cognitive functions, whereas the transient depletion of Tregs accelerated the onset of cognitive decline (Dansokho et al., 2016).